HOME>Investor Relations

Investor Relations

Share Price Information

IR Calendar

2018
July 30
Announcement of FY2018 1st Quater Financial Results
June 22
The 11th Ordinary General Meeting of Shareholders
May 9
Announcement of FY2017 Financial Results

What's New

  • RSS
  • About RSS

News Release List

2018
July 30 Topics IR Meeting for FY2018 1st Quarter Business Results[Material][Audio]
July 30 Release Announcement of FY2018 1st Quarter Financial Results
⇒R&D Pipeline "State of New Product Development"
July 27 Release Mitsubishi Tanabe Pharma's MT-7117 Receives U.S. FDA Fast Track Designation for the Investigational Treatment of Patients with the Ultra-Rare Disease, Erythropoietic ProtoporphyriaPDF
July 19 Release Mitsubishi Tanabe Pharma Receives The 43rd (FY2018) Inoue Harushige Prize ― A challenge for the new drug against amyotrophic lateral sclerosis (ALS), research and development of edaravone―PDF
July 2 Release Mitsubishi Tanabe Pharma and Osaka University co-found the “Department of Neuro-Medical Science” - Toward the Innovative Drug Discovery for refractory Neurological Diseases -PDF
July 2 Release Open Call for Applicants for Researcher-Initiated Clinical Research Funds - We Ensure Transparency and Support Investigator-Initiated Research Based on Japan's Clinical Research Act -PDF
June 28 Release Mitsubishi Tanabe Pharma and Janssen Pharmaceutical K.K. update co-promotion framework for STELARA, an anti-IL-12/23p40 monoclonal antibody Distribution will be transferred to Mitsubishi Tanabe Pharma, while the two companies will continue co-promotion of STELARA to treat adults with Crohn’s disease in JapanPDF
June 25 Topics Corporate Governance Report
June 22 Topics Notice of Resolution of the 11th Ordinary General Meeting of Shareholders
⇒Results of the Exercise of Voting Rights(June 25, 2018)
June 14 Release TFDA approves Clenafin/Jublia for the treatment of Onychomycosis in TaiwanPDF
May 30 Release Notice Regarding Establishment of Immune-mediated Inflammatory Diseases Consortium for Drug Development―Start of collaborative/competitive drug discovery research by three academic institutions and three pharmaceutical companiesPDF
May 28 Release For the ALS patients in the world,we hope to deliver Japan-originated ALS treatment―EMA accepts our filing for Edaravone to treat ALSPDF
May 25 Topics Notice of Convocation of the 11th Ordinary General Meeting of Shareholders
May 18 Release Canagliflozin (Antidiabetic agent) wins The Technology Award Grand Prize fromthe Japan Chemical Industry Association (JCIA)PDF
May 10 Topics IR Meeting for FY2017 Business Results[Material][Video]
May 9 Release Announcement of Financial Results for FY2017
⇒R&D Pipeline "State of New Product Development"
April 10 Release Update of Previous Disclosure ― Announcement of Filing a Request for Arbitration on the Licensing Agreement with Kolon Life SciencePDF
April 10 Release To ALS patients in the world, we hope to deliver Japan-originated ALS treatment―Health Canada accepts our filing for Edaravone to treat ALS and we established commercializing company in CanadaPDF
March 26 Release Mitsubishi Tanabe Pharma and Hitachi Utilize AI Technology to Begin Collaborative Creation for Improving Efficiency of Clinical Trials for New Drug DevelopmentPDF
March 6 Release Name Change of our Singapore SubsidiaryPDF
March 1 Release Mitsubishi Tanabe Pharma Group started marketing CANAGLU Tablets 100mg, a treatment agent for type 2 diabetes mellitus in TaiwanPDF
February 28 Release Valixa Tablet 450mg ―Public knowledge-based application for an additional pediatric indication for the prevention of CMV disease in organ transplant patients as well as application for an additional dosage form of dry syrupPDF
February 5 Topics IR Meeting for FY2017 3rd Quarter Business Results[Material][Audio]
February 5 Release Announcement of FY2017 3rd Quarter Financial Results
⇒R&D Pipeline "State of New Product Development"
January 23 Release Swissmedic accepts our filing for Edaravone to treat ALS ― To ALS patients in the world, we hope to deliver Japan-originated ALS treatmentPDF
January 16 Release Approval in China Received for Additional Novastan Indication for Acute Cerebral Infarction ― Reinforcing Our Pharmaceutical Development and Sales in China, the World's Second Largest Pharmaceutical MarketPDF
January 11 Release Launch of "KREMEZIN Tablets 500mg" (Additional Formulation), Drug for Chronic Renal Failure ― For Improving Patients' Usage Experience and Medication Adherence ―PDF
  • FTSE4Good
  • FTSE Blossom Japan
  • MSCI日本株女性活躍指数
  • MSCIジャパンESGセレクトリーダーズ指数
  • JPX-NIKKEI 400

Investor Relations

Share Price Information

ReadSpeaker docReader makes documents accessible to all users including users with vision problems letting users view and listen to texts.
User guide